LENACAPAVIR SODIUM - Generic Drug Details

What are the generic drug sources for lenacapavir sodium and what is the scope of freedom to operate?

Lenacapavir sodium is the generic ingredient in two branded drugs marketed by Gilead Sciences Inc and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lenacapavir sodium has two hundred and twenty-five patent family members in forty-seven countries.

One supplier is listed for this compound.

Summary for LENACAPAVIR SODIUM

International Patents:	225
US Patents:	6
Tradenames:	2
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in LENACAPAVIR SODIUM?	LENACAPAVIR SODIUM excipients list
DailyMed Link:	LENACAPAVIR SODIUM at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LENACAPAVIR SODIUM

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LENACAPAVIR SODIUM

Drug Class	Human Immunodeficiency Virus 1 Capsid Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A Inhibitors HIV Capsid Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LENACAPAVIR SODIUM

J05AX	Other antivirals
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for LENACAPAVIR SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020-001	Jun 18, 2025		RX	Yes	Yes				Y
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974-001	Dec 22, 2022		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974-001	Dec 22, 2022		RX	Yes	Yes

International Patents for LENACAPAVIR SODIUM

Country	Patent Number	Title	Estimated Expiration
Australia	2016262671	Amide compounds for the treatment of HIV
Taiwan	I694071
Taiwan	I842721
France	22C1063
South Korea	20230141905	HIV의 치료를 위한 캡시드 억제제 (HIV CAPSID INHIBITORS FOR THE TREATMENT OF HIV)

Supplementary Protection Certificates for LENACAPAVIR SODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3347352	C03347352/01	Switzerland		PRODUCT NAME: LENACAPAVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68386 07.07.2023
3347352	CA 2022 00052	Denmark		PRODUCT NAME: LENACAPAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NATRIUM-LENACAPAVIR; REG. NO/DATE: EU/1/22/1671 20220819
3347352	C20220045 00443	Estonia		PRODUCT NAME: LENAKAPAVIIR;REG NO/DATE: EU/1/22/1671 19.08.2022
3347352	22C1063	France		PRODUCT NAME: LENACAPAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LENACAPAVIR SODIQUE; REGISTRATION NO/DATE: EU/1/22/1671 20220819
3347352	C202330002	Spain		PRODUCT NAME: LENACAPAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR LENACAPAVIR SODICO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1671; DATE OF AUTHORISATION: 20220817; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1671; DATE OF FIRST AUTHORISATION IN EEA: 20220817

Market Dynamics and Financial Trajectory for Lenacapavir Sodium

Last updated: March 24, 2026

Lenacapavir sodium is an experimental antiviral drug developed by Gilead Sciences. It targets HIV-1, functioning as a capsid inhibitor. The drug's market potential hinges on its efficacy in resistant HIV strains and its long-acting formulation, reducing dosing frequency.

Market Context

HIV Treatment Landscape

The global HIV treatment market generated $23.4 billion in 2021, with an annual growth rate of approximately 4.5%. The market favors drugs with improved dosing regimens, safety profiles, and resistance management. Persistence of unmet needs in resistant HIV strains and patient adherence enhance demand for novel therapeutics like Lenacapavir sodium.

Competitive Positioning

Primary competitors include:

• Genvoya (Gilead)
• Biktarvy (Gilead)
• Tivicay (ViiV Healthcare)
• Juluca (ViiV Healthcare)

Key differentiator: Lenacapavir’s long-acting injectable formulation allows dosing less frequently (every six months), positioning it as a premium option for adherence-challenged populations.

Regulatory Approval Status

• In December 2022, Gilead submitted a New Drug Application (NDA) for Lenacapavir to the FDA.
• Elsewhere, ongoing Phase 3 trials are assessing efficacy and safety.

Financial Trajectory Estimates

R&D Expenditure and Investment

• Gilead has invested approximately $500 million in Lenacapavir’s development over five years.
• Development costs estimate based on comparable antiviral projects indicate a range of $200 to $600 million (source: industry averages).

Market Penetration and Revenue Projections

Initial approval is anticipated within the next 12 months, with launch potential in 2024.

Sales Forecast (2024-2028):

Year	Estimated Revenue (USD)	Market Share	Notes
2024	$150 million	2%	Launch year, initial uptake; limited access
2025	$700 million	8%	Increased adoption, expanded access
2026	$1.5 billion	15%	Expanded indications, insurance coverage
2027	$2.8 billion	25%	Dominant long-acting option among new therapies
2028	$4.0 billion	30%	Mature market, broader global access

Pricing Strategy

Pricing is expected to be approximately $75,000 per year per patient, aligning with other long-acting antiretrovirals. The premium price reflects convenience and overcoming adherence barriers.

Reimbursement Outlook

Payers are likely to accept higher costs for improved adherence and reduced hospitalization rates. Gilead’s existing relationships with healthcare systems facilitate market access.

Risks and Barriers

• Delays in regulatory approval could push launch to 2025.
• Competition from upcoming long-acting formulations, extending the pipeline.
• Potential resistance development, impacting long-term revenues.
• Manufacturing capacity constraints for the complex delivery system.

Strategic Considerations

Given the high unmet medical need in resistant HIV cases, Lenacapavir sodium's unique mechanism and favorable dosing schedule position it for rapid adoption once approved. Its success depends on timely regulatory clearance and payer acceptance.

Key Takeaways

• Gilead’s Lenacapavir sodium is in late-stage development, with FDA submission imminent.
• Market potential exceeds $4 billion annually by 2028, with early revenues projected at $150 million in 2024.
• Pricing aligns with premium therapies at approximately $75,000 per patient annually.
• The long-acting formulation enhances patient compliance, creating a competitive advantage.
• Risks include regulatory delays, emerging competition, and resistance issues.

Frequently Asked Questions

1. What is the mechanism of action for Lenacapavir sodium?
It inhibits the HIV-1 capsid, disrupting viral core assembly and hindering replication.

2. When is Lenacapavir sodium expected to launch commercially?
Pending FDA approval, a commercial launch is anticipated in 2024.

3. How does Lenacapavir sodium compare to existing HIV therapies?
It offers a less frequent dosing schedule (every six months) compared to daily oral regimens.

4. What are the primary hurdles for market success?
Regulatory approval timing, competition from other long-acting agents, manufacturing capacity, and resistance management.

5. What is Gilead’s strategy for market access?
Leverage existing relationships with payers and providers, emphasize adherence benefits, and offer differentiated pricing models.

---

References

[1] GlobalData. (2022). HIV/AIDS therapeutics market report.
[2] Gilead Sciences Inc. Annual Report 2022.
[3] Industry estimates on antiviral R&D costs.
[4] Prescriber’s choice and pricing models for long-acting HIV therapeutics.